openPR Logo
Press release

Primary Immunodeficiency Diseases Market to Rise to US$7.5 bn by 2023

08-29-2017 02:29 PM CET | Health & Medicine

Press release from: TMR - Research Reports

Primary Immunodeficiency Diseases Market to Rise to US$7.5 bn

The global primary immunodeficiency diseases market was recorded at US$4.4 bn in 2014. It is expected to exhibit a CAGR of 6.10% within a forecast period from 2015 to 2023. The market could hold a potential value of US$7.6 bn by the end of 2023, according to a research report released by Transparency Market Research. The report, titled “Primary Immunodeficiency Diseases Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023,” is a descriptive compilation of analytical efforts taken to understand this market by industry expert analysts.

Perceive the Report Details for Primary Immunodeficiency Diseases Market: http://www.transparencymarketresearch.com/primary-immunodeficiency-disease-market.html

PIDD is a group of rare diseases that are genetic in nature. The commonality among PIDDs is that a section of the immune system is either non-functional or missing. General symptoms of PIDD include extremely low resistance to serious infections or illnesses. This also includes damage to organs as well as life-threatening cases where a body’s immune system starts attacking cells and tissues generated in the body itself. The most common method of treating PIDDs is through the use of human plasma. There are extreme cases of PIDD where a patient will need complete stem cell replacement.

The report explains the global PIDD market using four criteria for categorization: disease, test, treatment, and geography.

On the basis of disease, the global PIDD market is divided into the segments of innate immune disorders, cellular immunodeficiency, and antibody deficiency. Each of these can be further divided into multiple sub-segments consisting of specific diseases and syndromes. The report states that the segment of antibody deficiency diseases topped the global PIDD market in 2014. It is also expected to be the fastest-growing segment of the market in the given forecast period, owing to the high prevalence of antibody deficiency diseases. On average, about 60% to 70% of PIDD cases registered have been from this segment.

The most common, and therefore the most medically significant, antibody deficiency disease is common variable immune deficiency. CVID affects about one in 25,000.

On the basis of test, the global PIDD market is segmented into blood testing and prenatal testing. Of these, the market was led by prenatal tests in 2014 in terms of revenue, owing to the expensive nature of the tests. Prenatal tests are also the first type of test that parents opt for while diagnosing their offspring for PIDD.

In the event that parents find out that the fetus is expected to suffer from PIDDs, they are given the option to discontinue the pregnancy. At the same time, parents who have shown signs of passing on autosomal recessive diseases are also given the option of artificial insemination.

On the basis of treatment, the global PIDD market is divided into immunoglobulin replacement therapy, stem cell and gene therapy, antibiotic therapy, and others. The report expects immunoglobulin replacement therapies to be the fastest-growing segment of the global PIDD market for the given forecast period.

On the basis of geography, the global PIDD market was dominated by North America in 2014, owing to a high rate of diagnosis, the presence of advanced medical care, and the high level of research and development efforts being taken by the top players in this region. In comparison, Asia Pacific and Rest of the World are expected to show a slow rate of growth in the global PIDD market, due to low awareness rates.

Request for the Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3137

The key players in the global PIDD market are Grifols S.A., Octapharma AG, LFB S.A., Kedrion S.p.A., Bio Products Laboratory Ltd., CSL Behring LLC, Biotest AG, and Baxter International, Inc.

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Immunodeficiency Diseases Market to Rise to US$7.5 bn by 2023 here

News-ID: 689508 • Views: 184

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for PIDD

Primary Immunodeficiency Diseases Market is expected to reach US$7.5 bn by the e …
As per Transparency Market Research, the global primary immunodeficiency market stood at US$4.3 bn in 2014. Rising at a CAGR of 6.1% between 2015 and 2023, the market is expected to reach US$7.5 bn by the end of 2023. Prevalence of Unmet Medical Needs in Emerging Economies to Create Opportunities for Market’s Growth However, a significant scope for expansion of PIDD diagnostic lies in emerging nations. These nations report a
Primary Immunodeficiency Diseases Market is rising at a CAGR of 6.1% till 2023
As per Transparency Market Research, the global primary immunodeficiency market stood at US$4.3 bn in 2014. Rising at a CAGR of 6.1% between 2015 and 2023, the market is expected to reach US$7.5 bn by the end of 2023. Prevalence of Unmet Medical Needs in Emerging Economies to Create Opportunities for Market’s Growth However, a significant scope for expansion of PIDD diagnostic lies in emerging nations. These nations report a
Primary Immunodeficiency Diseases Market is Expected to Rise at a Remarkable CAG …
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market. These companies have been
Primary Immunodeficiency Diseases Market: Key Insights
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market. These companies have been
Worldwide Primary Immunodeficiency Diseases Market Opportunities: New Born Scree …
Primary immunodeficiency diseases (PIDD) comprise a group of 200+ immune disorders wherein a part of the body’s immune system is either absent or does not function properly. The conditions, which result because of a single-gene defect, are passed down from either one or both parents. In the most common form, PIDDs occur due to problems in DNA that result in a lack of white blood cells, which the immune system
Comparative Analysis: Global Primary Immunodeficiency Diseases Market, by Geogra …
As per Transparency Market Research, the global primary immunodeficiency market stood at US$4.3 bn in 2014. Rising at a CAGR of 6.1% between 2015 and 2023, the market is expected to reach US$7.5 bn by the end of 2023. Primary Immunodeficiency Diseases Market: Key Insights In response to the rising incidence of antibody diseases, Transparency Market Research (TMR) forecasts the global primary immunodeficiency market to surge at 6.1% CAGR between 2015 and